The Horizons Dialogue with Alexandra Beckstein

The Quantum Advantage: Will Quantum Computing Redefine Drug Discovery, Longevity, and Healthcare?

Alexandra Beckstein is CEO and Co-Founder of QAI Ventures, a Swiss-based global venture capital platform investing across Quantum Tech and Enabling Technologies, from pre-seed through Series C.

Having led QAI Ventures from inception, Beckstein has scaled a portfolio of over 35 early-stage and growth ventures. Under her leadership, the firm established a distinctive tripartite model integrating a dedicated venture capital fund, regional accelerator hubs across Switzerland, Singapore, and Canada, and an institutional corporate innovation platform designed to commercialize deep-tech IP alongside industry partners. A strategic voice in Switzerland’s National Quantum Strategy, Beckstein advises at the intersection of public policy, academic research, and sovereign technology deployment. Her overarching thesis centers on the structural transition of quantum mechanics from theoretical research to industrial deployment—identifying the capital allocators and ecosystem builders who institutionalize this architecture as the primary drivers of 10-year multi-industry transformation, particularly across life sciences and advanced computing.

1. The Global Vision & Paradigm Shift

"QAI Ventures operates at the convergence of quantum mechanics and artificial intelligence. How does quantum computing fundamentally transform longevity, healthcare, and drug discovery from a traditional wet-lab experiment into a precise, predictive computational science?"

Alexandra: Quantum computing's potential in this space lies in modeling molecular and biological systems with a precision classical computing can't reach - turning drug discovery from years of iterative wet-lab trial-and-error into something closer to predictive computational design. We see this playing out across our portfolio: companies like Kvantify and MQS are applying quantum and quantum-inspired methods to pharma-relevant problems, while DryLabz is pushing dry-lab simulation as a genuine alternative to physical experimentation.

A strong example of how Quantum Computing can add value in the life science industry is the Quantum Innovation Challenge, a global initiative inviting researchers, students, and startups to explore how quantum technologies can transform life sciences. Last year's challenge tackled one of pharma's most persistent hurdles: determining the right drug dose in early-stage clinical trials, using a synthetic dataset and quantum or quantum-inspired approaches to PK/PD modeling. QAI Ventures has taken an active role in this initiative, and our portfolio company MQS is one of its core organizers - a clear example of how our companies help pull quantum computing into real pharmaceutical R&D, not just theoretical promise. THE HORIZONS Perspective: Empirical wet-lab R&D has long operated as a capital-intensive, high-friction bottleneck—where multi-million-dollar clinical failures compress asset valuations. Quantum-backed predictive modeling fundamentally reconfigures this unit economic model. By converting chemical discovery from stochastic trial-and-error into deterministic digital simulations, capital allocators can de-risk early-stage biotech assets long before clinical capital is deployed. In the macro landscape of longevity, computational precision is not merely a technical efficiency—it is the foundational infrastructure required to scale healthspan solutions with institutional certainty.

2. De-Risking Deep-Tech & Biotech Capital

"Biotech venture capital has historically been bound by multi-year timelines and high capital risk. From an investment perspective, how does QAI Ventures' quantum validation model de-risk early-stage deep-tech capital and shorten time-to-market for LPs and institutional investors?"

Alexandra: Biotech's traditional venture model is built around long, capital-intensive timelines with limited visibility into whether a scientific approach will actually work until years in. QAI Ventures is structured differently. We're not a pure-play fund: We pair early-stage capital with accelerator programs that put founders directly in front of quantum specialists and industry partners before we scale our investment.

That means a startup's technical claims get pressure-tested by domain experts and validated against real industry problems early, rather than assumed on the strength of a pitch deck. For LPs, this translates into a more disciplined filter: capital moves toward companies whose quantum approach has already been stress-tested in an applied setting, which shortens the distance between technical proof-of-concept and a credible commercial path, reducing some of the blind-faith risk that has historically defined deep-tech and biotech investing.

THE HORIZONS Perspective: De-risking deep-tech capital is fundamentally an exercise in sovereign time compression. The primary friction in early-stage biotech is not capital availability, but the asymmetry of information between technical claims and commercial viability. Stress-testing quantum IP in applied industry settings creates an operational arbitrage—filtering out non-viable science before Series A deployment. For institutional capital allocators, this validation framework shortens the gestation period between proof-of-concept and commercial monetization, maximizing internal rates of return (IRR) across frontier assets.

3. Track Record, Portfolio Figures & Commercial Impact

"With an expanding global portfolio and strong post-program capital multiplication, could you showcase a few standout portfolio metrics or deal examples where QAI Ventures' capital and ecosystem directly accelerated a startup's valuation and commercial trajectory?"

Alexandra: Our track record reflects the model working. QAI Ventures has built one of the most active portfolios in the space: more than 35 investments, two exits within two years, and portfolio companies that have gone on to raise over USD 250 million in follow-on capital from global players including IBM, GitHub, Toshiba, and the European Investment Bank.

What stands out isn't just the volume of deals, but the trajectory: companies that came through our accelerator with early, validated technical footing have consistently found it easier to raise credible follow-on capital, because investors further down the chain trust that the underlying science has already been tested against real industry use cases.

THE HORIZONS Perspective: In deep-tech asset management, capital multiplication is the ultimate stress test of fund architecture. Generating over USD 250 million in follow-on financing across 35+ ventures demonstrates how early-stage technical validation functions as an institutional trust signal. When tier-one technology conglomerates and sovereign investment banks back portfolio assets, it confirms that pre-investment de-risking mitigates early scientific friction—transforming high-complexity quantum IP into a liquid, institutional-grade venture pipeline.

4. The APAC Launchpad & Singapore Accelerator

"Zooming into your expansion with Enterprise Singapore—where your inaugural Singapore cohort is taking root—why is Singapore the ideal launchpad for deploying quantum infrastructure into the broader Asian life sciences market?"

Alexandra: Singapore is more than a gateway to Asia: It's a deep-tech powerhouse with world-class research institutions, a strong IP regime, and a clear national strategy to lead in quantum technologies and AI. With nearly S$300 million committed to quantum innovation, a dense startup ecosystem, and a globally connected financial hub, it's the natural base for founders ready to build and scale quantum ventures.

That's why QAI Ventures chose Singapore as the site of our Asia-Pacific headquarters, bringing our full venture capital, acceleration, and venture-building model to the region's entrepreneurial ecosystem - in partnership with Enterprise Singapore. Our inaugural Singapore cohort is our first step in translating that infrastructure into real portfolio companies, and we see it as the launchpad for connecting Asia's life sciences and deep-tech talent to the same validation model that's driven our results in Europe. THE HORIZONS Perspective: For institutional investors navigating Asia’s rapid life sciences expansion, market entry hinges on legal stability, IP sovereignty, and capital efficiency. Singapore’s strategic commitment of nearly S$300M toward quantum infrastructure creates an ideal environment for sovereign co-investment and deep-tech scaling. Establishing a dual-axis pipeline between European research networks and Singapore's regulatory ecosystem allows capital allocators to capture cross-border arbitrage—deploying computational health assets across Asia’s high-growth healthcare markets with strong institutional protection.

5. The Horizon & Future Frontier

"With the details surrounding your upcoming September 17 event and the ongoing growth of your accelerator cohorts globally, what is the ultimate horizon you are building toward at the intersection of quantum computing, capital deployment, and human vitality over the next decade?"

Alexandra: Over the next decade, we're building toward a world where Quantum Tech is no longer a research curiosity but a working part of how breakthroughs in industry, including life sciences, get made. QAI Ventures exists to compress the distance between deep scientific insight and real-world deployment bringing together founders, capital, and industry so promising quantum science doesn't stall in the lab.

Our Quantum Global Summit reflects that ambition: rather than a conference built around speakers, it's built around our startups, bringing the full ecosystem - researchers, corporates, investors, and policymakers - together around the companies actually doing the work. From Singapore, we will also have our current cohort joining the Summit. As our accelerator cohorts grow globally, from Switzerland to Singapore to Canada, the horizon we're building toward is one where quantum-backed innovation is known for its successful industry application across sectors – with life science being one of the earliest industries to see benefits. THE HORIZONS Perspective: Long-term capital creation requires identifying technology transitions before they become consensus trades. Over a ten-year horizon, quantum computing will shift from an emerging technology asset into the fundamental operating infrastructure of bio-pharmaceuticals, advanced material science, and personalized human optimization. By constructing a multi-regional ecosystem spanning Europe, North America, and Asia, early platform builders are securing systemic distribution channels. For global investors, backing this structural transformation offers exposure to the foundational architecture that will dictate commercial performance and competitive advantage across life sciences for decades to come.

Extending Horizons. Elevating Life.